FDA Drug recall D-0149-2024
Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distrib…
- FDA Drug
- Class III
- completed
- Published 2023-12-20
On 2023-12-20 the FDA classified a Class III recall of Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distrib… by Siegfried Barbera Sl, citing failed Dissolution Specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0149-2024 |
| Classification | Class III |
| Status | completed |
| Initiated | 2023-11-20 |
| Published | 2023-12-20 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Siegfried Barbera Sl |
| Distribution | US |
Product
Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66
Reason
Failed Dissolution Specifications
Identifiers
| ndc | 0078-1077-66 |
|---|---|
| code_info | Lot# ME2713; Exp. 02/2025 Lot # MF8286, ML1860; Exp. 04/2025 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0149-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.